Literature DB >> 1771308

Antibiotic therapy of pleural empyema.

C E Hughes1, R E Van Scoy.   

Abstract

Most empyemas occur as a complication of pneumonia or lung abscess, but 15% to 30% occur after thoracic surgery and 10% occur in association with an intraabdominal infection. The bacteriology of empyemas that occur in association with lung infections is often polymicrobial and mixed, containing multiple species of both aerobic and anaerobic bacteria, the latter found in up to 75% of cases. In contrast, empyema following thoracic surgery is more likely to be monomicrobial and caused by common nosocomial pathogens such as Staphylococcus aureus and aerobic gram-negative bacilli. Diffusion of antibiotics into both infected and uninfected pleural fluid is good, but certain agents (aminoglycosides and some beta-lactams) may be inactivated in the presence of pus, low pH, and beta-lactamase enzymes. Single antibiotic agents that are likely to be active against the wide spectrum of potential pathogens include imipenem-cilastatin and ticarcillin-clavulanic acid. Combinations of antibiotics should include an effective agent against anaerobic bacteria (clindamycin, metronidazole) coupled with an agent active against aerobic gram-positive cocci and gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1771308

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  9 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Effect of pH on in vitro antimicrobial susceptibility of the Bacteroides fragilis group.

Authors:  M E Falagas; L McDermott; D R Snydman
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Pleural effusion.

Authors:  A R Medford; A Medford; N Maskell
Journal:  Postgrad Med J       Date:  2005-11       Impact factor: 2.401

Review 4.  Perioperative antibiotics in thoracic surgery.

Authors:  Stephanie H Chang; Alexander S Krupnick
Journal:  Thorac Surg Clin       Date:  2011-10-20       Impact factor: 1.750

Review 5.  Nanomedicine to fight infectious disease.

Authors:  Kathryn M Rubey; Jacob S Brenner
Journal:  Adv Drug Deliv Rev       Date:  2021-10-08       Impact factor: 15.470

6.  Empyema thoracis: a problem with late referral?

Authors:  C W Cham; S M Haq; J Rahamim
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

7.  JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committee Respiratory Infectious Disease WG.

Authors:  Keiichi Mikasa; Nobuki Aoki; Yosuke Aoki; Shuichi Abe; Satoshi Iwata; Kazunobu Ouchi; Kei Kasahara; Junichi Kadota; Naoki Kishida; Osamu Kobayashi; Hiroshi Sakata; Masahumi Seki; Hiroki Tsukada; Yutaka Tokue; Fukumi Nakamura-Uchiyama; Futoshi Higa; Koichi Maeda; Katsunori Yanagihara; Koichiro Yoshida
Journal:  J Infect Chemother       Date:  2016-06-15       Impact factor: 2.211

8.  Sustained release of bactericidal concentrations of penicillin in the pleural space via an antibiotic-eluting pigtail catheter coated with electrospun nanofibers: results from in vivo and in vitro studies.

Authors:  Yin-Kai Chao; Cheng-Hung Lee; Kuo-Sheng Liu; Yi-Chuan Wang; Chih-Wei Wang; Shih-Jung Liu
Journal:  Int J Nanomedicine       Date:  2015-05-04

9.  A study of empyema thoracis and role of intrapleural streptokinase in its management.

Authors:  Amit Banga; G C Khilnani; S K Sharma; A B Dey; Naveet Wig; Namrata Banga
Journal:  BMC Infect Dis       Date:  2004-06-29       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.